PhaseII/III double-blind comparative study of the efficacy and safety of TAK-536CCB when coadministered with hydrochlorothiazide in patients with grade I or II essential hypertensio
Phase 2
- Conditions
- Hypertension
- Registration Number
- JPRN-jRCT2080221917
- Lead Sponsor
- TAKEDA PHARMACEUTICAL COMPANY LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Grade I or II essential hypertension.
- At both Week -2 and Week 0, sitting blood pressure (measured in the examination room) satisfied the following criteria:
Systolic blood pressure: >=150 mmHg and <180 mmHg
Diastolic blood pressure: >=95 mmHg and <110 mmHg, etc.
Exclusion Criteria
Secondary hypertension, malignant hypertension or grade III hypertension.
Significant white-coat hypertension
Sleep apnea syndrome requiring treatment
Clinically defined hepatic disorder
Clinically defined renal disorder
Significantly low or high levels of K or Na in body fluids, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method